Bayer HealthCare Pharmaceuticals has announced the decision to introduce a new advertising campaign for Yaz, one of the most popular oral contraceptives in the United States. This time the television ads will warn that nobody should take the contraceptive in the hope that it will cure pimples or premenstrual syndrome.

 

According to a statement from the attorneys general, Bayer improperly marketed the contraceptive to treat symptoms of premenstrual syndrome even though it did not have the U.S. Food and Drug Administration’s approval. The drug is approved by the FDA to treat a condition known as premenstrual dysphoric disorder, or PMDD, with symptoms like anxiety, tension and persistent anger.

 

“This case is a strong example of federal-state collaboration to stop the unlawful marketing of prescription drugs,” Attorney General Cordray was quoted as saying.

The judgement filled in Massachusetts' Suffolk Superior Court, resolves allegations that Bayer's 2008 marketing of Yaz violated the terms of the 2007 agreement by not disclosing the uses for which Yaz has been approved by the U.S. Food and Drug Administration.

 

“Resolving this matter is not only in the best interests of Bayer, but also the interests of patients who rely on Yaz for contraception,” Bayer said in a statement. However, the company did not officially admit to any wrongdoing.

Last year, the company received two warning letters from the FDA as a response to Bayer’s decision to illegally market two unapproved aspirin medication. The FDA warned the company that treatments for heart disease and osteoporosis must be reviewed by government scientists and cannot be sold over the counter.